Holen Sie sich die Stockscreener-App
0.00
100.00%
-3.41
Handel nachbörslich:
3.41
3.41
+
Opthea Limited Adr Aktie (OPT) Neueste Nachrichten
Millennium Management LLC Reduces Stock Holdings in Opthea Limited (NASDAQ:OPT) - Defense World
Citadel Advisors LLC Takes $79,000 Position in Opthea Limited (NASDAQ:OPT) - Defense World
Opthea Limited (NASDAQ:OPT) Given Average Recommendation of “Hold” by Brokerages - Defense World
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and ALX Oncology Holdings (ALXO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), ACADIA Pharmaceuticals (ACAD) and Quanterix (QTRX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail
Opthea Limited (NASDAQ:OPT) Given Average Rating of “Hold” by Analysts - Defense World
Sarepta Therapeutics (SRPT) Gets a Buy from Oppenheimer - The Globe and Mail
Brokerages Set Opthea Limited (NASDAQ:OPT) PT at $1.33 - Defense World
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Opthea Ltd shares corporate update in SEC filing - Investing.com
Opthea Halts Wet AMD Clinical Trials By Investing.com - Investing.com South Africa
Opthea Halts Wet AMD Clinical Trials - Investing.com
Opthea Limited (NASDAQ:OPT) Receives $1.33 Consensus PT from Brokerages - Defense World
Hold Rating Issued for Opthea Limited Amid Uncertainty Following Phase 3 Trial Failure - TipRanks
Opthea Limited: Hold Rating Amid Phase 3 Trial Failure and Financial Uncertainty - TipRanks
Opthea’s COAST Phase 3 Trial Fails to Meet Primary Endpoint, Raising Financial Concerns - TipRanks
Opthea COAST trial misses primary endpoint, enters talks with DFA Investors - TipRanks
Opthea reports phase 3 trial results for eye treatment - Investing.com
Promising Developments and Strong Financial Position Propel AbSci’s Growth Prospects - TipRanks
Opthea Limited Announces New Securities Quotation on ASX - TipRanks
Opthea Limited Reports Increased Losses Amid Clinical Advancements - TipRanks
Optimistic Buy Rating for Opthea Limited Driven by Promising Phase 3 Trials and Innovative AMD Treatment - TipRanks
Opthea reports mid-year financial results - Investing.com
Opthea Ltd completes key drug product campaign - Investing.com
Opthea Completes Key Phase 3 Trial Milestone in Wet AMD Treatment - TipRanks
Opthea Limited completes week 52 patient visits in the COAST trial - Ophthalmology Times
Optimistic Outlook and Buy Rating for Opthea Limited Amid Promising Phase 3 Trials and Strong Financial Position - TipRanks
Opthea to Present at Oppenheimer Healthcare Conference - GlobeNewswire Inc.
OPTOpthea Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Is Opthea Limited (OPT) One of the Best ASX Stocks to Buy According to Hedge Funds? - Insider Monkey
Opthea Unveils Promising Wet AMD Therapy at Investor Day - TipRanks
Why Opthea (OPT) Is Among the Best Australian Stocks to Buy Now? - Yahoo Finance
Jane Street Group LLC Invests $114,000 in Opthea Limited (NASDAQ:OPT) - Defense World
Opthea’s Innovative Approach to AMD Treatment with Sozinibercept - TipRanks
Opthea to Host Investor Days in New York and Australia - The Manila Times
Opthea Sets Key 2025 Investor Events to Showcase Breakthrough Wet AMD Treatment Sozinibercept - StockTitan
Opthea Limited Reports Earnings Results for the Half Year Ended December 31, 2024 - Marketscreener.com
Opthea to Present Phase 3 Trial Update at J.P. Morgan Healthcare Conference - TipRanks
Race Oncology bolsters leadership - The Australian
Opthea Highlights Innovative Wet AMD Therapy - TipRanks
Opthea CEO to Present at Citi Healthcare Conference, Spotlights Eye Disease Treatment - StockTitan
Opthea Limited Targets AMD Market with Sozinibercept - TipRanks
Opthea Appoints Kathy Connell to Board of Directors - The Manila Times
Opthea's Wet AMD Program Featured at Ophthalmology Events - The Manila Times
Is Opthea Limited (OPT) the Penny Stock with the Biggest Upside Potential According to Analysts? - Yahoo Finance
Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025 - The Manila Times
Opthea Limited Announces Chief Financial Officer Changes -October 07, 2024 at 05:52 pm EDT - Marketscreener.com
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024 - StockTitan
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept - Stock Titan
'Blockbuster opportunity': This speculative ASX stock could rise 70% - The Motley Fool Australia
2 Stocks Under $10 Wall Street Says Are 'Strong Buys' - Barchart.com
11 Best ASX Stocks To Buy Now - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):